Recent Investments & Expansions
Now offering the following enhancements:
- 2X more large animal capacity for fast and flexible study starts
- Options for EU-compliant housing
- Full-service IND-enabling packages for Biologics
- New Immunotoxicology & immunology and cell culture laboratories
- Disease model testing for COPD, IBD, Tumor xenografts, NASH, hepatitis and fibrosis
- Connected scientific and regulatory expertise enabling dual filing in the U.S. and China and large molecule IND-enabling studies